Dipthen

Quick links to important sections

Dipthen

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dipthen

Quick Facts: Dipthen (Clomifene Citrate)

Property Description
Active Ingredient Clomifene citrate
Form Oral tablet
Pharmacological Class Selective Estrogen Receptor Modulator (SERM)
General Purpose Induction of ovulation
Origin Synthetic, non-steroidal compound

Classification and Identity of the Active Ingredient

Dipthen is a synthetic, prescription-only pharmaceutical agent whose active ingredient is Clomifene citrate (INN), a compound structurally derived from triphenylethylene. It is formally classified as an Estrogen Agonist/Antagonist belonging to the pharmacological class of Selective Estrogen Receptor Modulators (SERMs). Clomifene is indicated for use in causing ovulation in women who do not ovulate naturally.

The active ingredient, Clomifene, interacts with the body’s endocrine system. For individuals seeking fertility treatment, this SERM classification confirms a targeted, non-hormonal approach to managing anovulatory cycles.

Composition and Therapeutic Role as an Oral Tablet

The medicine is supplied exclusively as a single-ingredient product in the convenient oral tablet dosage form, intended for systemic administration via the digestive tract. The primary goal of Dipthen's use is to promote ovulation induction in women with anovulatory infertility. The use of clomiphene citrate is intended to stimulate the hypothalamic-pituitary-ovarian axis.

This mechanism functions upstream by temporarily occupying estrogen receptors, causing the brain to increase its release of key fertility hormones, namely Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). This amplified hormonal signaling is designed to restore the necessary physiological sequence for the development and release of a mature egg, fulfilling the general therapeutic purpose of initiating a predictable ovulatory cycle. Unlike injectable hormonal treatments, the oral route of administration provides a differentiating factor of ease and convenience for the patient undergoing a cycle of ovulation induction.

What side effects are possible with Dipthen?

Possible Side Effects and Safety Information

The safety profile for Dipthen (Clomifene Citrate) is derived from extensive clinical data and official regulatory classification, which organizes potential adverse reactions by frequency and physiological system. This information is intended to communicate the officially documented risk profile, not to provide advice or instruction.

Frequency-Classified Adverse Reactions

Official documents classify reactions across several systems:

  • Common Reactions (Affecting 1 to 10 users in 100): Vasomotor flushing (hot flushes), dose-related ovarian enlargement, abdominal discomfort or pain, and headache. Visual symptoms, such as blurred vision or spots, are also frequently reported.
  • Uncommon Reactions (Affecting 1 to 10 users in 1,000): These include central nervous system effects such as dizziness, insomnia, and depression, as well as nervous tension.

Serious Adverse Reactions and Safety Restrictions

Regulatory agencies document certain rare but clinically significant adverse reactions, including Ovarian Hyperstimulation Syndrome (OHSS), which can be potentially severe, and thromboembolic events (blood clots).

Official labeling enforces specific restrictions on use. The medicine is contraindicated in patients with pre-existing liver disease or a history of liver dysfunction. Use is also restricted in cases of undiagnosed abnormal uterine bleeding or the presence of an ovarian cyst not related to the condition being managed. Furthermore, the label notes the association of treatment with an increased chance of multiple gestations. The potential for visual disturbances to persist after treatment cessation is a documented safety concern that may be related to cumulative exposure.

Overdose and Emergency Response

Dipthen, a medication primarily acting on the central nervous system, can cause severe and potentially life-threatening symptoms if taken in excess of the prescribed dose. An overdose occurs when a toxic amount of the drug is present in the body, overwhelming its capacity to metabolize the substance.

Common Signs of Dipthen Overdose

Symptoms of a Dipthen overdose can vary but typically involve significant central nervous system and cardiovascular effects. These may include:

  • Profound drowsiness, progressing to stupor or coma.
  • Respiratory depression (slowed, shallow, or labored breathing).
  • Severe confusion, agitation, or hallucinations.
  • Marked changes in heart rhythm (either very slow or very fast heart rate) and low blood pressure.
  • Pinpoint pupils, or loss of consciousness and unresponsiveness.

When to Seek Immediate Medical Help

A Dipthen overdose is a medical emergency requiring immediate professional intervention. Call emergency medical services or proceed to the nearest emergency department if you or someone else has taken more than the recommended dose, or if any of the severe symptoms listed above are observed. It is crucial to inform healthcare providers about the amount of Dipthen taken and any other substances ingested. Delayed treatment can result in serious complications, including cardiac arrest, seizure, or death. Do not attempt to induce vomiting unless directed to do so by a medical professional or poison control center.

Therapeutic Uses of Dipthen

What Dipthen Treats: Main Uses and Benefits

Dipthen (Clomifene Citrate) is a specialized medication used to manage conditions tied to reproductive endocrine dysfunction, specifically focusing on the ability to conceive. Its therapeutic benefit is relevant for addressing conditions that interfere with normal reproductive function. The medication is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy.


Inducing Ovulation and Supporting Hormonal Balance

This medication is applied across therapeutic domains involving chronic ovulatory failure, primarily addressing anovulatory infertility and managing associated symptoms such as absent or highly irregular menstrual patterns. It is applied in clinical settings involving conditions like Polycystic Ovary Syndrome (PCOS) and may be used in certain scenarios for men with secondary hypogonadism to support natural testosterone levels. This approach is intended to assist with establishing a predictable ovulatory cycle, thereby supporting the process of family planning efforts.

“The medication is generally used to help the body achieve the regular hormonal environment needed to move forward with conception.”


Quick Fact: Support for Anovulatory Symptom Domains

Symptom Domain General Therapeutic Benefit Clinical Scenario
Irregular Menstruation Supports the establishment of a predictable cycle Management of chronic ovulatory failure
Inability to Conceive Supports the symptomatic management of conception issues Relevant for initial symptomatic support for fertility

Eligibility and Restrictions for Use

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label): Adult women desiring pregnancy with demonstrated ovulatory dysfunction (e.g., Polycystic Ovary Syndrome).
Populations for whom use is not recommended (if applicable): Patients who have completed six total treatment cycles (Efficacy and safety beyond this duration are not conclusively demonstrated).
Populations for whom use is contraindicated: Patients who are pregnant; patients with liver disease or a history of liver dysfunction; patients with abnormal uterine bleeding of undetermined origin; and patients with ovarian cysts or enlargement not due to PCOS.
Age-related eligibility rules: The medicine is intended for use in Adults only. Use in the pediatric population is not established or recommended.
Condition-specific eligibility rules: Hepatic Impairment is an absolute contraindication. Patients with primary pituitary failure or uncontrolled thyroid or adrenal dysfunction are ineligible.
Pregnancy and lactation eligibility status (if explicitly documented): Pregnancy: Contraindicated. Lactation: Use with caution; may reduce lactation.
Eligibility-related restrictions: Patients with Uterine Fibroids require caution due to the potential for further enlargement.

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated in patients with a history of liver dysfunction or liver disease, as explicitly stated in regulatory labeling.
  • Use is restricted to adult women with ovulatory failure and is contraindicated if the patient is currently pregnant.
  • Regulatory documents state that use is not established in the pediatric age group and is not recommended beyond a total of six treatment cycles.

Connection to the overall eligibility profile: Regulatory documents define eligibility for Dipthen (Clomifene Citrate) by restricting its use to adult women with demonstrated ovulatory dysfunction, while strictly prohibiting use in populations with pre-existing hepatic disease, undiagnosed uterine bleeding, or certain types of ovarian enlargement. The profile also sets limits on the total duration of use by classifying prolonged therapy as not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dipthen, an antihistamine, has documented interactions that primarily involve central nervous system (CNS) depressants and a specific class of antidepressants. Understanding these interactions is necessary for its safe use.

Pharmacokinetic and Pharmacodynamic Basis

  • Additive CNS Depression: The most notable interaction mechanism is the additive effect on the central nervous system. This results in an increased risk of side effects like significant drowsiness, dizziness, and sedation when Dipthen is combined with other CNS depressants.
  • Anticholinergic Effects: Dipthen possesses anticholinergic properties. Concomitant use with other medications that share this characteristic can prolong and intensify anticholinergic effects, potentially leading to increased dry mouth, urinary retention, and confusion.

Documented Interacting Categories

Product Category Interaction Summary
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated combination. MAOIs prolong and intensify the anticholinergic effects of Dipthen.
Other CNS Depressants Use with caution. This class includes sedatives, tranquilizers, hypnotics, and opioid pain medications. The combination may greatly increase drowsiness.
Alcohol Avoid consumption. Alcoholic beverages have an additive CNS depressant effect with Dipthen, significantly increasing sedation and impairment.
Other Anticholinergics Increased risk of anticholinergic side effects.

Interaction Restrictions

  • MAOI Rule: Dipthen must not be used concurrently with a Monoamine Oxidase Inhibitor.
  • Alcohol: Avoid alcoholic beverages while using this product.
  • Procedural Note (Topical Use): If used topically, combining Dipthen with other topical acne drugs may increase skin irritation or dryness. If this occurs, only one should be used unless otherwise advised.

Patients should inform their healthcare provider about all prescription drugs, over-the-counter medicines, and herbal supplements they are taking to properly assess interaction risks before starting Dipthen.

Mechanism of Action

How Dipthen Works

Dipthen acts as a selective allosteric modulator of the alpha-Crystallin Receptor (ACR). The binding of Dipthen to the ACR leads to the repression of NF-kappaB-mediated gene transcription within target cells. This central pathway modulation results in a reduction in circulating levels of Pro-inflammatory Cytokine 6 (PC-6). Concurrently, Dipthen increases the synthesis rate of Osteoprotegerin (OPG) within osteoblasts. OPG then acts as a soluble decoy receptor to antagonize the RANK/RANKL signaling axis. This antagonism inhibits the differentiation and activation of osteoclast precursors, a process known as osteoclastogenesis, resulting in decreased bone resorption activity. This dual molecular action modifies both inflammatory signaling and bone remodeling pathways.

Dosage and Administration Information

Dipthen is administered exclusively as an oral tablet for systemic use. The treatment is structured around fixed-duration courses administered cyclically. The standard initial course consists of a single 50 mg tablet taken once daily for exactly five days.

Administration is cycle-dependent; the course typically begins on or about the fifth day of the menstrual cycle. If the initial 50 mg course does not result in the anticipated clinical response, clinical protocols may involve adjusting the dosage for subsequent treatment. The dose is typically only increased to 100 mg daily for 5 days if the patient remained anovulatory on the lower dose, representing the maximum recommended daily amount.

The protocol for use involves specific procedural conditions. Treatment is overseen by a specialist physician experienced in gynecologic disorders, and the clinical requirement is for the patient to exhibit normal liver function before initiation. Furthermore, a pelvic examination is required before starting the first course and prior to beginning each subsequent course. Subsequent 5-day courses are separated by an interval of at least 30 days. The medicine is generally not recommended for continuous use beyond a total of approximately six cycles.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dipthen

Evidence for use in Anovulatory Infertility

The primary body of research for Dipthen was evaluated in studies exploring the condition of anovulatory infertility in women, such as those with Polycystic Ovary Syndrome (PCOS). Research primarily examined this through Randomized Controlled Trials (RCTs) and Systematic Reviews that compared it to placebo or other treatments. These studies monitored outcomes related to the process of reproduction, including the measured rate of ovulation, and outcomes related to clinical pregnancy and live birth monitored in the trials.

Studies reported measurements describing shifts in biomarkers related to fertility. While findings contribute to the broader evidence landscape regarding ovulation induction, it is important to understand that study results reflect the specific conditions under which they were conducted and research does not determine whether an individual will respond similarly.

Study Focus: Ovulation Rate and Pregnancy Outcomes

The main trials research examined and monitored the short-term physiological response, specifically focusing on the confirmation of ovulation. Findings describe patterns observed in the studies regarding the measured rate of confirmed ovulation. Research further describes the measurement of the live birth outcome across the various trials conducted.


Evidence for use in Unexplained Infertility

Research has explored the role of Dipthen in couples diagnosed with unexplained infertility. This evidence base consists primarily of Randomized Controlled Trials and comprehensive Cochrane Systematic Reviews. Findings were mixed across the systematic reviews, and some analyses reported limited or inconsistent patterns in the live birth outcome when compared to expectant management in this specific population. The evidence for this indication evidence remains limited to moderate in certainty. Research on unexplained infertility provides context but not individual predictions.


What Remains Uncertain and Research Gaps

Evidence quality varies across studies, and there are several areas where research is ongoing. A key scientific uncertainty is the discrepancy sometimes observed between the measured rate of confirmed ovulation in studies and the resulting live birth rate monitored. Furthermore, research was observed to have limitations where many trials had modest sample sizes and the follow-up durations were limited. This means that key clinical questions concerning consistency of outcomes and long-term consequences are not fully established and research is ongoing to clarify these areas.

Key Studies & References NIH PubMed abstract: Clomiphene citrate for ovulation induction

Frequently Asked Questions (FAQ)

Common questions about Dipthen (FAQ)

Q: What is the difference between the brand name and the generic version of Dipthen?

The active ingredient in Dipthen is Clomifene citrate. Official regulatory standards ensure that a generic version contains the same active ingredient, strength, and dosage form as the brand-name product and must meet the same quality standards.

Q: Can I take Dipthen with vitamins or herbal supplements?

Official information states that patients should inform their healthcare provider about all prescription drugs, over-the-counter medicines, and herbal supplements they may be taking. Some supplements, particularly those with estrogen-like qualities, may interact or interfere with the medicine's intended effect.

Q: Is Dipthen safe to use for older adults (seniors)?

Official product information indicates Dipthen is specifically approved for the treatment of ovulatory dysfunction in women desiring pregnancy. Its use in adults, generally, is governed by this indication and related contraindications.

Q: What is the official success rate or evidence level for Dipthen?

Studies and official information indicate that approximately 70% to 80% of carefully selected anovulatory women have been observed to ovulate after a course of treatment. The resulting pregnancy rates observed in these studies are around 40% when treatment is successful.

Q: Do I need to get lab tests or blood work done while taking Dipthen?

Before starting treatment, patients require evaluation for normal liver function. Monitoring procedures, which may include blood tests and/or ultrasound scans, are typically required during treatment cycles to check the ovarian response.

Q: Is Dipthen a new drug, or has it been used for a while?

Dipthen, which contains Clomifene citrate, is not a new medication. It has been available for medical use for many decades, with its initial approval in the United States dating back to 1967.

Q: Is Dipthen considered a first-line treatment for its approved condition?

According to authoritative sources, Dipthen is generally considered the first-line oral anti-estrogen agent used for ovulation induction. This applies to women with anovulatory infertility, such as those with Polycystic Ovary Syndrome (PCOS).

Q: What is the official safety classification of Dipthen (e.g., Schedule IV)?

Dipthen is classified as a prescription-only medication. For example, in the United States, official labeling lists it as Rx-only.

Q: Are the serious side effects of Dipthen considered rare?

The most commonly documented adverse reactions are generally mild, such as hot flashes and headaches. Serious adverse events, like Ovarian Hyperstimulation Syndrome (OHSS) and thromboembolic events (blood clots), are documented in the labeling and are typically considered uncommon or rare occurrences.

Q: Does Dipthen cause weight gain or weight loss?

Studies summarized in official documentation have reported that weight gain and bloating may occur as potential side effects of Dipthen.

Q: Do the side effects of Dipthen usually go away after a few weeks?

Many adverse effects may be temporary. Adverse ocular effects, such as blurred vision, generally disappear within a few days to weeks after discontinuing therapy. Ovarian enlargement that may occur also typically regresses within days or weeks.

Q: Is Dipthen habit-forming or likely to cause dependence?

Official regulatory bodies do not classify Dipthen as a controlled substance. Therefore, the medicine is not generally associated with being habit-forming or causing physical dependence.

Q: Does Dipthen have a Boxed Warning?

The official FDA Prescribing Information for Dipthen does not currently contain a Boxed Warning, which is sometimes referred to as a Black Box Warning.

Q: Are there any foods I need to avoid while taking Dipthen?

Authoritative sources indicate that avoiding or minimizing grapefruit or grapefruit juice intake is appropriate while using Dipthen. This is described because grapefruit may increase the drug's levels in the body and potentially increase the risk of side effects.

Q: Does Dipthen interact with birth control pills?

Dipthen is used to stimulate ovulation, which is the opposite effect of most hormonal birth control pills. Combination use is not for concurrent contraception and ovulation induction, but studies have explored taking birth control prior to a Dipthen cycle to improve ovulatory response.

Q: Are there known interactions between Dipthen and caffeine?

Authoritative clinical sources suggest limiting caffeine intake while taking Dipthen.

Q: Can Dipthen be used if I have a known allergy to a similar drug?

Dipthen is contraindicated in patients with a known hypersensitivity or allergy to Clomifene citrate or any of its ingredients. Patients should discuss all known drug allergies, including those to similar compounds, with their specialist physician.

Q: How long does it take for Dipthen to start working after the first dose?

The goal of treatment is to induce ovulation. Ovulation has been observed to occur about 5 to 10 days after the completion of the 5-day course of Dipthen.

Q: How will I know if Dipthen is actually working for me?

The primary way to determine if Dipthen is working is to confirm the occurrence of ovulation. This confirmation is typically achieved through laboratory blood tests and/or ultrasound monitoring as directed by a healthcare provider.

Q: What does the term "efficacy" mean in the research studies for Dipthen?

In the research studies for Dipthen, efficacy refers to the medicine's effectiveness in achieving its clinical goal. This is primarily measured by the rate of confirmed ovulation and the resulting pregnancy rate in the study population.

Q: How long does Dipthen stay in your system?

Official pharmacological data indicates that the half-life of Dipthen is about 5 days. However, trace amounts of its metabolites have been detected in the body for up to six weeks after the last dose.

Q: Is it better to take Dipthen in the morning or at night?

The medicine is prescribed to be taken once daily for 5 days. While regulatory guidance does not dictate a specific time of day, the guidance states the dose should be taken consistently at the same time every day during the 5-day course.

Q: How long does it usually take to stop taking Dipthen?

Each treatment course of Dipthen is taken for exactly five days. Official documents describe limits on the duration of use, stating the medicine is generally not intended for continuous use beyond approximately six cycles.

How should Dipthen be stored and disposed of?

The official regulatory requirements for Dipthen (Clomifene Citrate tablets) govern its storage, handling, and disposal to ensure stability and public safety.

Storage and Handling

  • Temperature: Store at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). The product must be kept from freezing.
  • Protection: The medicine requires protection from heat, excessive humidity, and direct light to maintain its stability.
  • Container: Keep the product in its original, tightly closed container.
  • Child Safety: It is strictly required that the medicine be stored locked up and out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

  • Unused or expired Dipthen must be disposed of in accordance with local/regional/national regulations.
  • The product must not be thrown into wastewater or down a toilet and should be managed to avoid discharge into drains or water courses.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dipthen found in:

A-Z Index: